Download PDF
CC BY 4.0 · World J Nucl Med
DOI: 10.1055/s-0044-1788278
Original Article

Exploring the Use of Ambientally Stored Methylene Diphosphonate Radiopharmaceutical Aliquots in Solving Challenging Situations in Developing Countries

Jenipher None Zulu 
1   Pharmacy/School of Health Sciences, Levy Mwanawasa Medical University, Zambia
,
Reuben None Katebe
2   Department of Technology and Science, Ministry of Higher Education, Lusaka, Zambia
3   Department of Nuclear Science, National Institute for Scientific Research, Lusaka, Zambia
,
Martalena None Ramli
4   Department of Radiopharmaceuticals, Centre for Radiopharmaceutical Production, Indonesia
,
Rita None Sakala
5   Department of Nuclear Medicine/Radiopharmacy Unity, University Teaching Hospital, Zambia
,
Elias None Mwape
6   Department of Nuclear Medicine, University Teaching Hospital, Zambia
,
Ernest None Chipasha
7   Office of the Deputy Commandant, Northern Command Military Hospital, Zambia
,
Bernard Mudenda Hang'ombe
8   School of Veterinary Medicine, University of Zambia, Zambia
› Author Affiliations
› Further Information
Also available at
   Permissions and Reprints

Abstract

Objectives The primary aim was to evaluate the prolonged quality characteristics of methyl diphosphonate (MDP) aliquots during ambient storage over a specified duration. This study further investigated potential additives that could enhance the stability of MDP aliquots stored under such conditions.

Materials and Methods This was a laboratory-based experimental study conducted at the University Teaching Adult Hospital in Lusaka, Zambia. A total of 36 MDP aliquots stored at ambient conditions and 4 MDP aliquots stored at conventional refrigerated frozen conditions were labeled with technitium-99m (99mTc) and tested for radiochemical purity (RCP) and other quality characteristics. A comparative analysis of the stability and quality of MDP aliquots from the two cohorts was then conducted.

Statistical Analysis Stata 14 was used to analyze the data on the RCP of all MDP aliquots.

Results The RCP of ambient stored MDP aliquots was found to be ranging from 98 to 99%, while that for frozen and refrigerated ones ranged from 99 to 100%. There was also a 1% increase in RCP for both cohorts with argon gas purging (98 and 99%, respectively).

Conclusion The RCP of MDP aliquots from both cohorts was much higher than the required minimum of 90% implying that there was no significant association of their stability and quality with the mode of storage. However, purging with argon gas seemed to increase the stability further in both streams. The study findings show potential for application in resource-constrained environments and centers, especially in developing countries, where challenges to maintain the cold storage chain of these important radiopharmaceuticals are likely to be encountered due to power outages.

Keywords

radiopharmaceutical - technetium - methylene diphosphate - ambient conditions - radiochemical purity

Statement of Conforming to the Declaration of Helsinki

Authority to conduct this research was obtained from all the relevant authorities and these include the Zambia National Health Research Authority, Management of the University Teaching Adult Hospital, and ERES Converge Ethical Committee. To further safeguard the safety of researchers, the general public, and the environment, Standard Operating Procedures for the use of RPs were adhered to the Zambia Radiation Protection Authority standard.




Publication History

Article published online:
04 July 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Weber WA, Johannes C, Carolyn JA. et al. The future of nuclear medicine, molecular imaging, and theranostics. J Nucl Med 2020; 2 (61) 263S-272S
    CrossrefPubMedGoogle Scholar
  • 2 Vallabhajosula S, Berna DP, John WB. Molecular imaging of prostate cancer: radiopharmaceuticals for positron emission tomography (PET) and single-photon emission computed tomography (SPECT). Precision molecular pathology of prostate cancer 2018; 475-501
    CrossrefGoogle Scholar
  • 3 Dougherty DD, Rauch SL, Fischman AJ. Positron emission tomography and single photon emission computed tomography. Essentials Neuroimaging Clin Pract 2004; 13 (10) 75-82
    Google Scholar
  • 4 St James S, Bednarz B, Benedict S. et al. Current status of radiopharmaceutical therapy. Int J Radiat Oncol Biol Phys 2021; 109 (04) 891-901
    CrossrefPubMedGoogle Scholar
  • 5 Bombardieri E, Bonadonna G, Gianni L. Nuclear medicine in diagnosis and therapeutic options. Breast Cancer 2008; ••• DOI: 10.1007/978-3-540-36781-9.
    CrossrefGoogle Scholar
  • 6 Shende P, Gandhi S. Current strategies of radiopharmaceuticals in theranostic applications. J Drug Deliv Sci Technol 2021; 64: 102594
    CrossrefGoogle Scholar
  • 7 Urbain JL, Scott AM, Lee ST. et al. Theranostic radiopharmaceuticals: a universal challenging educational paradigm in nuclear medicine. J Nucl Med 2023; 64 (06) 986-991
    CrossrefPubMedGoogle Scholar
  • 8 Assaad T. New amino bisphosphonate compound for skeletal imaging: Comparison study with methylenediphosphonic acid (MDP) and (1-hydroxyethane-1, 1-diyl) diphosphonic acid (HEDP). Nukleonika 2016; 61 (01) 69-74
    CrossrefGoogle Scholar
  • 9 Chopra A. 99mTc-Methyl diphosphonate. Mol Imaging Contrast Agent Database 2009; 24: 1 (MICAD)
    Google Scholar
  • 10 Schillaci O, Filippi L, Manni C, Santoni R. Single-photon emission computed tomography/computed tomography in brain tumors. In Seminars in nuclear medicine. WB Saunders 2007; 01 (37) 34-47
    Google Scholar
  • 11 Lange R, Schreuder N, Hendrikse H. Radiopharmaceuticals: Practical Pharmaceutics: An International Guideline for the Preparation, Care and Use of Medicinal Products. Cham: Springer International Publishing; 2023: 531-550
    CrossrefGoogle Scholar
  • 12 Okarvi SM. Recent developments of prostate-specific membrane antigen (PSMA)-specific radiopharmaceuticals for precise imaging and therapy of prostate cancer: an overview. Clin Transl Imaging 2019; 7: 189-208
    CrossrefGoogle Scholar
  • 13 Vallabhajosula S, Lilja S, Brigitte V. A broad overview of positron emission tomography radiopharmaceuticals and clinical applications: what is new?. Seminars in nuclear medicine. WB Saunders 2011; 4 (41) 246-264
    Google Scholar
  • 14 Bayomy T, Abdulrazzak M, Moustafa H, Khalil WM, Pant GS. Radiopharmaceutical, original article different models for cost-effective fractionation of bone radiopharmaceuticals; methylene diphosphonate (MDP) & hydroxy methylene diphosphonate (HDP). Egypt J Nucl Med 2009; 2 (02) 74
    Google Scholar
  • 15 Fleming WK, Jay M, Ryo UY. Reconstitution and fractionation of radiopharmaceutical kits. J Nucl Med 1992; 33 (10) 1915
    PubMedGoogle Scholar
  • 16 Negi M, Dhingra M, Dhingra VK. Quality of radiochemical purity in multiple samples of various fractionated cold kits: testing a cost & time effective technique. Hell J Nucl Med 2019; 22 (03) 200-205
    PubMedGoogle Scholar
  • 17 Bhatia N, Dhingra VK, Watts A. et al. Fractionation of common cold kits as a cost-saving method in a low-volume nuclear medicine department. Indian J Nucl Med 2013; 3 (28) S36
    Google Scholar
  • 18 Penglis S, Tsopelas C. 99Tcm-tetrofosmin: evaluation of fractionated cold kits and two new methods of quality control. Nucl Med Commun 2000; 21 (05) 469-472
    CrossrefPubMedGoogle Scholar
  • 19 Bayomy T, Abdulrazzak M, Moustafa H, Khalil WM, Pant GS. Radiopharmaceutical, original article different models for cost-effective fractionation of bone radiopharmaceuticals; methylene diphosphonate (MDP) and hydroxymethylene diphosphonate (HDP). Egypt J Nucl Med 2009; 2: 74
    Google Scholar
  • 20 Thokchom AK, Kumar R, Bharati S. Vasumathi. Quality assessment of Tc-99m methylene diphosphonate (MDP) radiopharmaceutical prepared using different cold kit fractionation methods. Indian J Nucl Med 2022; 37 (01) 7-11
    CrossrefPubMedGoogle Scholar
  • 21 Decristoforo C, Siller R, Chen F, Riccabona G. Radiochemical purity of routinely prepared 99Tcm radiopharmaceuticals: a retrospective study. Nucl Med Commun 2000; 21 (04) 349-354
    CrossrefPubMedGoogle Scholar
  • 22 Waight LA, Cunnane CM, O'Brien LM, Millar AM. Effect of 99Tc on the radiochemical purity of 99mTc radiopharmaceuticals. Nucl Med Commun 2011; 32 (08) 752-756
    CrossrefPubMedGoogle Scholar